OR WAIT null SECS
Patricia Van Arnum was executive editor of Pharmaceutical Technology.
Astellas Pharma Inc. (Tokyo) will sell three European plants to the Temmler Group (Marburg, Germany), a pharmaceutical company and contract manufacturer. The move is part of Astellas's plan to reduce the number its production sites.
Tokyo (Dec. 21)
-Astellas Pharma Inc. (
) has agreed to transfer three European plants to the Temmler Group (Marburg, Germany), the pharmaceutical company and contract manufacturer. The move is part of Astellas's plan to reduce the number its production sites.
Asteallas will transfer to Temmler the bulk assets of its plants in Munich, Germany, and Klinge, Ireland, and all stocks of Produzioni Farmaceutiche Carugate S.r.l. The products currently manufactured at the plants will be sourced from Temmler, and Astellas will transfer roughly 400 employees to Temmler. The transfer of the facilities is scheduled to be completed January 1, 2007.
Astellas previously announced (in its mid-term five-year management plan, ending in fiscal year 2010) a plan to reduce the number of its production sites from the current 18 (nine in Japan and nine outside of Japan) to around 10.
Astellas will take a special charge of YEN 4.6 billion ($39 million) as a cost for streamlining the facilities in the fiscal year ending March 2007.
Astellas was formed in 2005 following the merger of Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd.